+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cryptococcosis Treatment Market by Drug Class, End User, Administration Route, Distribution Channel, Patient Type - Global Forecast to 2030- Product Image
Cryptococcosis Treatment Market by Drug Class, End User, Administration Route, Distribution Channel, Patient Type - Global Forecast to 2030- Product Image
Sale

Cryptococcosis Treatment Market by Drug Class, End User, Administration Route, Distribution Channel, Patient Type - Global Forecast to 2030

  • PDF Icon

    Report

  • 197 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5012985
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Cryptococcosis Treatment Market grew from USD 7.77 billion in 2024 to USD 8.24 billion in 2025. It is expected to continue growing at a CAGR of 5.96%, reaching USD 11.00 billion by 2030.

Navigating the Evolving Cryptococcosis Treatment Terrain

Cryptococcosis remains a critical global health challenge, with disease burden concentrated among immunocompromised populations and emerging as a threat beyond traditional risk groups. As pathogens evolve and therapeutic paradigms shift, healthcare stakeholders require a clear, concise overview of market dynamics and emerging opportunities. This executive summary delivers an authoritative introduction to the current landscape of cryptococcosis treatment, blending clinical insights, regulatory context, and market drivers.

Readers will gain an understanding of how shifts in diagnostic capabilities, patient demographics, and therapeutic innovations converge to influence the trajectory of antifungal development. By framing the market through a lens of unmet needs and commercial imperatives, this section sets the stage for deeper analysis. It underscores the importance of strategic agility in responding to treatment resistance, the demand for cost-effective regimens, and the imperative of equitable access in both high-income and resource-constrained settings.

Breakthrough Innovations Redefining Antifungal Strategies

In recent years, the cryptococcosis landscape has been transformed by breakthroughs in molecular diagnostics, advancements in antifungal drug design, and a more nuanced understanding of host-pathogen interactions. Rapid point-of-care assays now complement traditional microscopy and culture, enabling earlier detection and improving patient outcomes. Concurrently, novel drug candidates leverage targeted mechanisms to overcome biofilm-associated resistance, while liposomal formulations enhance safety profiles and dosing flexibility.

This convergence of diagnostic and therapeutic innovations is fueling a paradigm shift toward personalized treatment algorithms. Healthcare providers increasingly tailor regimens based on pathogen genotype, disease severity, and patient comorbidities. Moreover, strategic collaborations between biotech firms and academic institutions are accelerating translational research, driving new clinical trials and fostering a pipeline poised to meet the unmet needs of transplant recipients, HIV-infected patients, and those with no underlying immunodeficiency.

Navigating Tariff-Driven Cost Pressures in 2025

The implementation of adjusted tariffs in the United States for 2025 has had a marked influence on the cryptococcosis treatment market, reshaping procurement costs and strategic supply chains. Increased import duties on key active pharmaceutical ingredients have led to upward pricing pressure on several frontline therapies. Manufacturers have responded by optimizing raw-material sourcing and consolidating production to mitigate cost inflation and preserve margin integrity.

At the same time, these tariffs have prompted a recalibration of distribution strategies. Pharmaceutical companies are negotiating revised purchasing agreements with domestic suppliers to offset new tariff burdens, while distributors explore alternative logistics corridors to maintain price competitiveness. In parallel, healthcare payers and hospital systems are adjusting reimbursement policies, emphasizing pharmacoeconomic assessments and total cost of care models. This cumulative impact underscores the importance of regulatory agility and cost management in sustaining market growth and ensuring patient access to essential antifungal treatments.

Unpacking the Market with Five-Dimensional Segmentation

A nuanced view of market segmentation reveals critical drivers across five dimensions. In the realm of drug class, the market divides into Azoles, Flucytosine, and Polyenes, with Azoles further differentiated by fluconazole, posaconazole, and voriconazole, and Polyenes delineated by amphotericin B deoxycholate and its liposomal formulation. Analysis of end users shows that Clinics encompass both outpatient and specialist settings, while Hospitals range from secondary to tertiary care facilities, complemented by expanding Home Care services.

Administration routes offer another layer of insight, segmenting the market into intravenous delivery via central or peripheral lines and oral formats including suspensions and tablets. The distribution channel landscape features hospital pharmacies, online outlets, and retail pharmacies, each with distinct logistics and regulatory considerations. Lastly, patient type segmentation highlights populations with HIV infection and those without, the latter further classified into immunocompetent individuals and transplant recipients. Understanding these intersecting categories allows stakeholders to pinpoint growth pockets and align product development with real-world treatment pathways.

Decoding Regional Dynamics and Growth Catalysts

Regional dynamics shape demand patterns and competitive strategies. In the Americas, robust healthcare infrastructure and proactive public health initiatives drive high market penetration, particularly for advanced lipid-based formulations. However, disparity in access among underserved communities highlights the need for tailored distribution models and partnership programs. Across Europe, the Middle East & Africa, regulatory harmonization within the European Union contrasts with fragmented frameworks in emerging African markets, influencing approval timelines and pricing strategies.

Meanwhile, Asia-Pacific presents a dual narrative: established markets in Japan and Australia emphasize innovative therapies and precision diagnostics, while rapidly growing markets in Southeast Asia and India focus on affordability and scale. Governments in the region are investing in infectious disease surveillance and expanding reimbursement schemes, creating receptive environments for new antifungal products. These regional nuances demand bespoke market entry approaches that consider local regulatory, logistical, and socio-economic factors.

Strategic Moves Shaping Market Leadership

Leading players in the cryptococcosis treatment arena are distinguished by their integrated pipelines, strategic alliances, and commitment to clinical excellence. Large pharmaceutical corporations leverage global manufacturing networks and deep commercial teams to drive broad market access, while biotechnology firms focus on niche innovations such as pathogen-specific monoclonal antibodies and next-generation antifungals with novel mechanisms of action.

Several companies have fortified their portfolios through acquisitions of specialized R&D assets, bolstering late-stage development and enhancing lifecycle management of existing treatments. Collaborative consortiums between private enterprises and public health institutions are also shaping the competitive landscape, accelerating real-world evidence generation and facilitating early regulatory engagement. As intellectual property landscapes evolve and patent expirations loom, these strategic moves will determine each player’s ability to sustain differentiation and capture emerging market segments.

Five Strategies to Drive Competitive Advantage

Industry leaders must adopt a multi-pronged approach to capitalize on market opportunities. First, prioritizing investment in rapid diagnostic platforms will enable earlier intervention and improve patient outcomes, reinforcing the value proposition of high-cost therapies. Second, supply chain resilience can be enhanced by diversifying raw material sources and forging partnerships with local manufacturers to mitigate tariff-related disruptions.

Third, talent development in clinical affairs and health economics will support compelling value dossiers for payers, strengthening reimbursement negotiations. Fourth, engaging in collaborative research consortia with academic and governmental bodies can accelerate clinical development while sharing risk. Finally, customizing market entry strategies to regional regulatory landscapes-balancing speed with compliance-will ensure sustainable growth. By aligning operational agility with scientific innovation, organizations can secure competitive advantage and address the evolving needs of patients and healthcare systems.

Rigorous Multi-Source Methodology for Credible Insights

This report synthesizes insights from a rigorous, multi-source research methodology. Primary data were collected through in-depth interviews with key opinion leaders, infectious disease specialists, and procurement executives across major markets. Secondary research included a comprehensive review of peer-reviewed journals, regulatory filings, company annual reports, and trade publications, ensuring a holistic understanding of clinical, commercial, and regulatory dynamics.

Quantitative analyses employed a bottom-up approach to assess market share across segmentation dimensions, cross-verified with top-down industry benchmarks. Qualitative assessments leveraged Porter’s Five Forces and PESTEL frameworks to elucidate competitive pressures and macro-environmental factors. Triangulation of data sources and validation with subject matter experts reinforced accuracy and minimized bias. This robust methodological foundation ensures the report’s findings are both actionable and reliable for strategic decision-making.

Harnessing Insights to Guide Strategic Decision-Making

In an era defined by rapid scientific advances and shifting economic landscapes, the cryptococcosis treatment market exhibits both challenges and promise. Therapeutic innovation, coupled with evolving diagnostic capabilities, presents an opportunity to redefine standard of care and improve patient survival. Yet, cost pressures, regulatory complexities, and access disparities underscore the importance of strategic foresight.

By integrating segmentation analysis, regional nuance, and competitive intelligence, stakeholders can anticipate trends and allocate resources effectively. The insights detailed throughout this executive summary offer a roadmap for navigating uncertainty and capitalizing on emerging opportunities. Ultimately, success will hinge on the ability to blend scientific rigor with commercial acumen, ensuring that life-saving therapies reach those who need them most.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Drug Class
    • Azoles
      • Fluconazole
      • Posaconazole
      • Voriconazole
    • Flucytosine
    • Polyenes
      • Amphotericin B Deoxycholate
      • Liposomal Amphotericin B
  • End User
    • Clinics
      • Outpatient Clinics
      • Specialist Clinics
    • Home Care
    • Hospitals
      • Secondary Hospitals
      • Tertiary Hospitals
  • Administration Route
    • Intravenous
      • Central Line
      • Peripheral
    • Oral
      • Suspension
      • Tablet
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • Patient Type
    • HIV Infected
    • Non-HIV Infected
      • Immunocompetent
      • Transplant Patients
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Pfizer Inc.
  • Gilead Sciences, Inc.
  • Bausch Health Companies Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Fresenius SE & Co. KGaA
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Sun Pharmaceutical Industries Limited
  • Lupin Limited

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Cryptococcosis Treatment Market, by Drug Class
8.1. Introduction
8.2. Azoles
8.2.1. Fluconazole
8.2.2. Posaconazole
8.2.3. Voriconazole
8.3. Flucytosine
8.4. Polyenes
8.4.1. Amphotericin B Deoxycholate
8.4.2. Liposomal Amphotericin B
9. Cryptococcosis Treatment Market, by End User
9.1. Introduction
9.2. Clinics
9.2.1. Outpatient Clinics
9.2.2. Specialist Clinics
9.3. Home Care
9.4. Hospitals
9.4.1. Secondary Hospitals
9.4.2. Tertiary Hospitals
10. Cryptococcosis Treatment Market, by Administration Route
10.1. Introduction
10.2. Intravenous
10.2.1. Central Line
10.2.2. Peripheral
10.3. Oral
10.3.1. Suspension
10.3.2. Tablet
11. Cryptococcosis Treatment Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
12. Cryptococcosis Treatment Market, by Patient Type
12.1. Introduction
12.2. HIV Infected
12.3. Non-HIV Infected
12.3.1. Immunocompetent
12.3.2. Transplant Patients
13. Americas Cryptococcosis Treatment Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Cryptococcosis Treatment Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Cryptococcosis Treatment Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Pfizer Inc.
16.3.2. Gilead Sciences, Inc.
16.3.3. Bausch Health Companies Inc.
16.3.4. Teva Pharmaceutical Industries Ltd.
16.3.5. Viatris Inc.
16.3.6. Fresenius SE & Co. KGaA
16.3.7. Cipla Limited
16.3.8. Dr. Reddy's Laboratories Ltd.
16.3.9. Sun Pharmaceutical Industries Limited
16.3.10. Lupin Limited
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. CRYPTOCOCCOSIS TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. CRYPTOCOCCOSIS TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. CRYPTOCOCCOSIS TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. CRYPTOCOCCOSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. CRYPTOCOCCOSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. CRYPTOCOCCOSIS TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY FLUCONAZOLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POSACONAZOLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY VORICONAZOLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY FLUCYTOSINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AMPHOTERICIN B DEOXYCHOLATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY LIPOSOMAL AMPHOTERICIN B, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SPECIALIST CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SECONDARY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TERTIARY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CENTRAL LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PERIPHERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HIV INFECTED, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY IMMUNOCOMPETENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TRANSPLANT PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 72. CANADA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 73. CANADA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 74. CANADA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 75. CANADA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 76. CANADA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 77. CANADA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 78. CANADA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 79. CANADA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 80. CANADA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 81. CANADA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 82. CANADA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 83. CANADA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2030 (USD MILLION)
TABLE 84. MEXICO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 85. MEXICO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 86. MEXICO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 87. MEXICO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 88. MEXICO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 89. MEXICO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 90. MEXICO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 91. MEXICO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 92. MEXICO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 93. MEXICO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 94. MEXICO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 95. MEXICO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 116. ARGENTINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 117. ARGENTINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. ARGENTINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2030 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 133. UNITED KINGDOM CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 134. UNITED KINGDOM CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 135. UNITED KINGDOM CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 136. UNITED KINGDOM CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 137. UNITED KINGDOM CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 138. UNITED KINGDOM CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 139. UNITED KINGDOM CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 140. UNITED KINGDOM CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 141. UNITED KINGDOM CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 142. UNITED KINGDOM CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 144. UNITED KINGDOM CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2030 (USD MILLION)
TABLE 145. GERMANY CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 146. GERMANY CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 147. GERMANY CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 148. GERMANY CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 149. GERMANY CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 150. GERMANY CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 151. GERMANY CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 152. GERMANY CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 153. GERMANY CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 154. GERMANY CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 155. GERMANY CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 156. GERMANY CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2030 (USD MILLION)
TABLE 157. FRANCE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 158. FRANCE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 159. FRANCE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 160. FRANCE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 161. FRANCE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 162. FRANCE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 163. FRANCE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 164. FRANCE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 165. FRANCE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 166. FRANCE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 167. FRANCE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 168. FRANCE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2030 (USD MILLION)
TABLE 169. RUSSIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 170. RUSSIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 171. RUSSIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 172. RUSSIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 173. RUSSIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 174. RUSSIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 175. RUSSIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 176. RUSSIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 177. RUSSIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 178. RUSSIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 179. RUSSIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 180. RUSSIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2030 (USD MILLION)
TABLE 181. ITALY CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 182. ITALY CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 183. ITALY CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 184. ITALY CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 185. ITALY CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 186. ITALY CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 187. ITALY CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 188. ITALY CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 189. ITALY CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 190. ITALY CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 191. ITALY CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 192. ITALY CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2030 (USD MILLION)
TABLE 193. SPAIN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 194. SPAIN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 195. SPAIN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 196. SPAIN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 197. SPAIN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 198. SPAIN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 199. SPAIN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 200. SPAIN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 201. SPAIN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 202. SPAIN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 203. SPAIN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 204. SPAIN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2030 (USD MILLION)
TABLE 205. UNITED ARAB EMIRATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 206. UNITED ARAB EMIRATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 207. UNITED ARAB EMIRATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 208. UNITED ARAB EMIRATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 209. UNITED ARAB EMIRATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 210. UNITED ARAB EMIRATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 211. UNITED ARAB EMIRATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 212. UNITED ARAB EMIRATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 213. UNITED ARAB EMIRATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 214. UNITED ARAB EMIRATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 215. UNITED ARAB EMIRATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 216. UNITED ARAB EMIRATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2030 (USD MILLION)
TABLE 217. SAUDI ARABIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 218. SAUDI ARABIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 219. SAUDI ARABIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 220. SAUDI ARABIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 221. SAUDI ARABIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 222. SAUDI ARABIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 223. SAUDI ARABIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 224. SAUDI ARABIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 225. SAUDI ARABIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 226. SAUDI ARABIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 227. SAUDI ARABIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 228. SAUDI ARABIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2030 (USD MILLION)
TABLE 229. SOUTH AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 230. SOUTH AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 231. SOUTH AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 232. SOUTH AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 233. SOUTH AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 234. SOUTH AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 235. SOUTH AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 236. SOUTH AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 237. SOUTH AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 238. SOUTH AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 239. SOUTH AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 240. SOUTH AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2030 (USD MILLION)
TABLE 241. DENMARK CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 242. DENMARK CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 243. DENMARK CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 244. DENMARK CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 245. DENMARK CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 246. DENMARK CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 247. DENMARK CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 248. DENMARK CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 249. DENMARK CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 250. DENMARK CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 251. DENMARK CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 252. DENMARK CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2030 (USD MILLION)
TABLE 253. NETHERLANDS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 254. NETHERLANDS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 255. NETHERLANDS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 256. NETHERLANDS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 257. NETHERLANDS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 258. NETHERLANDS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 259. NETHERLANDS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 260. NETHERLANDS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 261. NETHERLANDS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 262. NETHERLANDS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 263. NETHERLANDS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 264. NETHERLANDS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2030 (USD MILLION)
TABLE 265. QATAR CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 266. QATAR CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 267. QATAR CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 268. QATAR CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 269. QATAR CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 270. QATAR CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 271. QATAR CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 272. QATAR CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 273. QATAR CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 274. QATAR CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 275. QATAR CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 276. QATAR CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2030 (USD MILLION)
TABLE 277. FINLAND CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 278. FINLAND CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 279. FINLAND CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 280. FINLAND CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 281. FINLAND CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 282. FINLAND CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 283. FINLAND CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 284. FINLAND CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 285. FINLAND CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 286. FINLAND CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 287. FINLAND CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 288. FINLAND CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2030 (USD MILLION)
TABLE 289. SWEDEN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 290. SWEDEN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 291. SWEDEN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 292. SWEDEN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 293. SWEDEN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 294. SWEDEN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 295. SWEDEN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 296. SWEDEN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 297. SWEDEN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 298. SWEDEN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 299. SWEDEN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 300. SWEDEN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2030 (USD MILLION)
TABLE 301. NIGERIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 302. NIGERIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 303. NIGERIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 304. NIGERIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 305. NIGERIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 306. NIGERIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 307. NIGERIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 308. NIGERIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 309. NIGERIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 310. NIGERIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 311. NIGERIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 312. NIGERIA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2030 (USD MILLION)
TABLE 313. EGYPT CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 314. EGYPT CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 315. EGYPT CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 316. EGYPT CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 317. EGYPT CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 318. EGYPT CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 319. EGYPT CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 320. EGYPT CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 321. EGYPT CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 322. EGYPT CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 323. EGYPT CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 324. EGYPT CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2030 (USD MILLION)
TABLE 325. TURKEY CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 326. TURKEY CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 327. TURKEY CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 328. TURKEY CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 329. TURKEY CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 330. TURKEY CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 331. TURKEY CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMIN

Companies Mentioned

The companies profiled in this Cryptococcosis Treatment market report include:
  • Pfizer Inc.
  • Gilead Sciences, Inc.
  • Bausch Health Companies Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Fresenius SE & Co. KGaA
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Sun Pharmaceutical Industries Limited
  • Lupin Limited

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages197
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 8.24 Billion
Forecasted Market Value ( USD ) by 2030 $ 11 Billion
Compound Annual Growth Rate5.9%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Cryptococcosis Therapeutics - Global Strategic Business Report - Product Image

Cryptococcosis Therapeutics - Global Strategic Business Report

  • Report
  • 473 Pages
  • Global
From
Cryptococcosis Treatment - Global Strategic Business Report - Product Image

Cryptococcosis Treatment - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
Cryptococcosis Market Report 2025 - Product Image

Cryptococcosis Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Cryptococcosis Market by Drug Class, Indication, Route Of Administration, End User, Distribution Channel, Patient Type - Global Forecast to 2030 - Product Image

Cryptococcosis Market by Drug Class, Indication, Route Of Administration, End User, Distribution Channel, Patient Type - Global Forecast to 2030

  • Report
  • 190 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.